Kinaction (masitinib) / AB Science  >>  Phase 3
Welcome,         Profile    Billing    Logout  

8 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kinaction (masitinib) / AB Science
2015-000897-36: A study to compare masitinib in combination with irinotecan to placebo in combination with irinotecan in the treatment of patients with esophagogastric adenocarcinoma Κλινική μελέτη για τη σύγκριση της μασιτινίμπης σε συνδυασμό με ιρινοτεκάνη έναντι του συνδυασμού placebo με ιρινοτεκάνη στη θεραπεία ασθενών με οισοφαγογαστρικό αδενοκαρκίνωμα

Ongoing
3
364
Europe
Masitinib, Irinotecan, AB1010, INEOF00997, Film-coated tablet, Concentrate for solution for infusion, IRINOTECAN/DEMO
AB science, AB science
Πatients with advanced-stage esophagogastric adenocarcinoma who have relapsed after first-line chemotherapy Ασθενείς με προχωρημένου σταδίου οισοφαγογαστρικό αδενοκαρκίνωμα οι οποίοι υποτροπίασαν μετά από την πρώτης γραμμής χημειοθεραπεία, Εsophagogastric adenocarcinoma Οισοφαγογαστρικό αδενοκαρκίνωμα, Diseases [C] - Digestive System Diseases [C06]
 
 
2021-002179-21: A phase 3 study to evaluate the safety and efficacy of masitinib as add-on therapy in patients with mild to moderate Alzheimer's disease treated with standard of care: cholinesterase inhibitors, memantine

Not yet recruiting
3
600
Europe
Masitinib, AB1010, Film-coated tablet
AB Science, ABScience, AB Science, ABScience
Alzheimer's disease, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT03127267 / 2019-001862-13: Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

Recruiting
3
495
Europe, US, RoW
Masitinib (6.0), AB1010, Riluzole, Rilutek, Placebo, Placebo Oral Tablet, Masitinib (4.5)
AB Science
Amyotrophic Lateral Sclerosis
12/23
12/23
NCT04333108 / 2016-001447-39: Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

Recruiting
3
140
Europe, RoW
Masitinib, AB1010, Placebo, Best Supportive Care
AB Science
Indolent Systemic Mastocytosis
12/24
06/25
MASIMS, NCT05441488 / 2021-000639-30: Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis

Recruiting
3
800
Europe, RoW
Placebo, Placebo Oral Tablet, Masitinib (4.5), AB1010
AB Science
Progressive Multiple Sclerosis
12/25
12/25
NCT05564169: Masitinib in Patients With Mild to Moderate Alzheimer's Disease

Not yet recruiting
3
600
Europe
Placebo, Placebo Oral Tablet, Masitinib (4.5), AB1010, Standard of care
AB Science
Alzheimer Disease
12/26
12/26
2010-021091-28: A clinical study to determine whether a new drug masitinib is safe and effective in cancer of the white blood cells.

Ongoing
2/3
267
Europe, RoW
Masitinib mesylate, Gemcitabine, Dexamethasone, AB1010, Film-coated tablet, Powder for infusion, Tablet, Gemcitabine, Dexamethasone
AB Science, AB Science
Relapsed or refractory peripheral T-cell lymphoma, Cancer of the white blood cells (T-lymphocytes), Diseases [C] - Cancer [C04]
 
 
2012-004222-25: Comparison of efficacy of masitinib versus placebo in the treatment of Crohn's disease

Ongoing
2/3
450
Europe
Masitinib, AB1010, Film-coated tablet
AB Science, AB Science
Crohn's disease, Inflammatory bowel disease, Diseases [C] - Digestive System Diseases [C06]
 
 

Download Options